SCRI Oncology Research Consortium

Sarah Cannon Research Institute (SCRI) is a premier global oncology research organization dedicated to advancing therapies for patients through community-based clinical trials. In 2022, SCRI merged its operations with McKesson's US Oncology Research to form a massive oncology research consortium, significantly expanding its clinical trial reach. The organization provides comprehensive clinical trial management and drug development services, ranging from first-in-human Phase 1 trials to late-stage pivotal studies. SCRI has been a key contributor to the clinical development of the majority of FDA-approved cancer therapies over the last decade. By partnering with pharmaceutical and biotech companies, the consortium provides patients with access to innovative treatments in their local communities across the United States and United Kingdom.